The AIDS epidemic in Lyon: Patient characteristics and defining illnesses between 1985 and 2000

HIV Medicine

Volumn 5, Issue 3, 2004, Pages 163-170

  Gayet Ageron, A ^a,b   Baratin, D ^a   Marceillac, E ^a   Allard, R ^c   Peyramond, D ^d   Chidiac, C ^d   Trepo, C ^e   Livrozet, J M ^a   Touraine, J L ^a   Ritter, J ^b   Sepetjan, M ^a   Fabry, J ^a,b   Vanhems, Philippe ^a,b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

^c MCGILL UNIVERSITY   (Canada)

^d CROIX ROUSSE HOSPITAL   (France)

^e HÔTEL DIEU   (France)

Author keywords

AIDS diagnosis; AIDS defining illnesses; Epidemiology; France; Non hodkin's lymphoma

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE DISTRIBUTION; ANALYSIS OF VARIANCE; ARTICLE; BISEXUALITY; CARCINOGENESIS; CHI SQUARE TEST; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; EPIDEMIC; FEMALE; FRANCE; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; ONSET AGE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SEX DIFFERENCE; SEXUAL INTERCOURSE; TIME; UNIVERSITY HOSPITAL;

EID: 2942661485     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2004.00205.x     Document Type: Article

References (29)

1. Egger M, Hirschel B, Francioli P et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. Br Med J 1997; 315: 1194-1199.
2. Mocroft A, Katlama C, Johnson AM et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000; 356: 291-296.
3. Institut de Veille Sanitaire. Surveillance du SIDA en France. Situation an 30 Septembre 2001. Bull Epidémiol Hebdomadaire 2002; 47: 207-214.
4. Vandentorren S, Mercie P, Marimoutou C et al. Trends in causes of death in the Aquitaine cohort of HIV-infected patients, 1995-1997. Eur J Epidemiol 1902; 17: 7-10.
5. Ancelle-Park R. Expanded European AIDS case definition. Lancet 1993; 341: 441.
6. Dormont J. Stratégies d'Utilisation des Antirétroviraux dans l'Infection par le VIH. Rapport 1998. Paris, France, Médecine-Sciences, Flammarian, 1998.
7. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997; 11: 1731-1738.
8. The CASCADE Collaboration. Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE. HIV Med 2000; 1: 224-231.
9. Gulick RM, Mellors JW, Havlir D et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-739.
10. The CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet 2000; 355: 1158-1159.
11. Hader SL, Smith DK, Moore JS, Holmberg SD. HIV infection in women in the United States: status at the millennium. JAMA 2001; 285: 1186-1192.
12. Hamers FF, Downs AM. HIV in central and eastern Europe. Lancet 2003; 361: 1035-1044.
13. Buira E, Gatell JM, Zamora L, Mallolas J, Miro JM, Soriano E. Analysis of 1,187 consecutive cases of AIDS: variations and trends in time. Enferm Infecc Microbiol Clin 1996; 14: 290-295, (in Spanish).
14. Johnson AM, Mercer CH, Erens B et al. Sexual behaviour in Britain: partnerships, practices, and HIV risk behaviours. Lancet 2001; 358: 1835-1842.
15. Samet JH, Freedberg KA, Stein MD et al. Trillion virion delay: time from testing positive for HIV to presentation for primary care. Arch Intern Med 1998; 158: 734-740.
16. Samet JH, Freedberg KA, Savetsky JB, Sullivan LM, Stein MD. Understanding delay to medical care for HIV infection: the long-term non-presenter. AIDS 2001; 15: 77-85.
17. Kaplan JE, Masur H, Holmes KK et al. An overview of the US Public Health Service/Infectious Diseases Society of America guidelines for preventing opportunistic infections in human immunodeficiency virus-infected persons. Clin Infect Dis 2000; 30 (Suppl: 1): S15-S28.
18. USPHS/IDSA, Prevention of Opportunistic Infections Working Group. Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Clin Infect Dis 2000; 30 (Suppl. 1): S29-S65.
19. Valdez H, Connick E, Smith KY et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002; 16: 1859-1866.
20. Weverling GJ, Mocroft A, Ledergerber B et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. The Eurosida Study Group. Lancet 1999; 353: 1293-1298.
21. Delmas MC, Schwoebel V, Heisterkamp SH, Downs AM, Ancelle-Park RA, Brunet JB. Recent trends in Pneumocystis carinii pneumonia as AIDS-defining disease in nine European countries. Coordinators for AIDS Surveillance. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9: 74-80.
22. Dore GJ, Li Y, Grulich AE et al. Declining incidence and later occurrence of Kaposi's sarcoma among persons with AIDS in Australia: the Australian AIDS cohort. AIDS 1996; 10: 1401-1406.
23. Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000; 96: 2730-2734.
24. Wolff AJ, O'Donnell AE. Pulmonary manifestations of HIV infection in the era of highly active antiretroviral therapy. Chest 2001; 120: 1888-1893.
25. Aboulafia D. Epidemiology and pathogenesis of AIDS-related lymphomas. Oncology (Huntingt) 1998; 12: 1068-1081.
26. Grulich AE, Wan X, Law MG et al. B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS 2000; 14: 133-140.
27. Jacobson LP, Yamashita TE, Detels R et al. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1999; 21 (Suppl. 1): S34-S41.
28. Buchbinder SP, Holmberg SD, Scheer S, Colfax G, O'Malley P, Vittinghoff E. Combination antiretroviral therapy and incidence of AIDS-related malignancies. J Acquir Immune Defic Syndr 1999; 21 (Suppl. 1): S23-S26.
29. Kirk O, Pedersen C, Cozzi-Lepri A et al. Non-Hodgkin's lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001; 98: 3406-3412.